Psychiatry and Neurology, Neurology · Georgetown, TX
NPI
1922237817
Since 2009
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
204 S Interstate 35 Ste 103
Georgetown, TX, 78628
Phone (512) 693-4041
Groups this clinician bills Medicare through
Medicare paid, 2024
$378K
33,725 services
Medicare patients, 2024
643
Average age 76
Drug cost, 2024
$3.3M
2,862 prescriptions
Company payments, 2025
$413K
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Soileau was code J0588 (injection, incobotulinumtoxin a, 1 unit), 29,060 times for 48 patients. In total Michael Soileau billed 33,725 services in 31 codes, and Medicare paid $378K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 29,060 | 48 | $4.08 | $119K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,172 | 511 | $12.40 | $15K |
| 99215 Office E&M - Established | Office | 802 | 375 | $131.98 | $106K |
| 99214 Office E&M - Established | Office | 639 | 387 | $91.10 | $58K |
| 95983 Electrical Nerve Conductivity | Office | 193 | 68 | $37.17 | $7,174 |
| 95984 Electrical Nerve Conductivity | Office | 186 | 54 | $33.65 | $6,259 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 142 | 84 | $24.88 | $3,533 |
| 99205 Office E&M - New | Office | 102 | 102 | $158.20 | $16K |
| 95874 Musculoskeletal | Office | 93 | 34 | $59.81 | $5,562 |
| 64616 Musculoskeletal | Office | 83 | 26 | $160.41 | $13K |
| 64612 Musculoskeletal | Office | 41 | 13 | $146.71 | $6,015 |
| 99213 Office E&M - Established | Office | 38 | 33 | $59.40 | $2,257 |
| 11105 Skin Biopsy | Office | 38 | 19 | $48.43 | $1,840 |
| 11104 Skin Biopsy | Office | 21 | 19 | $101.49 | $2,131 |
| 99204 Office E&M - New | Office | 20 | 20 | $137.53 | $2,751 |
By year: 2022 $435K for 36,626 services; 2023 $350K for 33,485 services; 2024 $378K for 33,725 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Soileau prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 442 prescriptions and refills. In total Michael Soileau wrote 2,862 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 442 | 1,008 | 158 | $16K |
| Rytary Carbidopa/Levodopa | 360 | 710 | 98 | $638K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 189 | 463 | 73 | $23K |
| Nuplazid Pimavanserin Tartrate | 121 | 165 | 20 | $784K |
| Primidone Generic | 111 | 263 | 41 | $4,030 |
| Clonazepam Generic | 103 | 264 | 45 | $1,085 |
| Donepezil Hcl Generic | 103 | 251 | 33 | $1,103 |
| Zonisamide Generic | 83 | 212 | 34 | $2,559 |
| Nourianz Istradefylline | 80 | 136 | 18 | $247K |
| Gocovri Amantadine Hcl | 73 | 95 | 17 | $162K |
| Gabapentin Generic | 71 | 153 | 23 | $1,196 |
| Amantadine Amantadine Hcl | 68 | 126 | 22 | $3,408 |
| Methadone Hcl Generic | 66 | 66 | Under 11 | $989 |
| Propranolol Hcl Generic | 55 | 135 | 24 | $1,428 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 54 | 118 | 19 | $1,052 |
Brand drugs: - claims; generic drugs: 1,937 claims; opioid claims: 66.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Soileau $413K ($279K in general payments such as food, travel and fees and $134K for research) from 17 companies. The largest payer was Amneal Pharmaceuticals LLC with $149K.
| Company | Payments | Amount |
|---|---|---|
| Amneal Pharmaceuticals LLC AMRX | 27 | $149K |
| Abbvie Inc. ABBV | 104 | $107K |
| Biogen, Inc. BIIB | 113 | $94K |
| Teva Pharmaceuticals USA, Inc. TEVA | 27 | $26K |
| Merz Pharmaceuticals, LLC | 40 | $18K |
| MDD US Operations, LLC | 15 | $8,785 |
| Abbott Laboratories ABT | 48 | $8,621 |
| Neurocrine BioSciences, Inc. NBIX | 18 | $290 |
| ACADIA Pharmaceuticals Inc ACAD | 12 | $223 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $93.32 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.